Hempstract, Inc. (OTCMKTS: HPST) is a vertically integrated hemp company specializing in the extraction, formulation, and distribution of phytocannabinoid-rich (PCR) hemp products. The company’s core business activities include proprietary extraction of cannabidiol (CBD) and other minor cannabinoids from industrial hemp, development of nanoemulsion technology for enhanced bioavailability, and manufacturing of finished consumer products under the Hempstract brand. These products range from tinctures, soft gels, and topical salves to inhalable formulations designed to meet the growing demand for standardized, high-purity cannabinoid offerings.
At the heart of Hempstract’s operations is its patent-pending micro-encapsulation process, which the company asserts improves solubility and absorption rates of cannabinoids when administered orally or through inhalation. By leveraging advanced supercritical CO2 extraction and chromatographic refinement, Hempstract is able to isolate specific cannabinoid and terpenoid profiles for tailored product formulations. The company also conducts in-house quality control testing, ensuring compliance with regulatory standards for potency, purity, and residual solvents.
Hempstract serves a diverse geographic footprint across North America, with production facilities and distribution channels in both the United States and Canada. Through partnerships with regional distributors, wellness retailers, and online marketplaces, the company reaches end users seeking natural alternatives in the health and wellness sector. Hempstract has also pursued strategic alliances with research institutions to explore new applications for hemp-derived compounds in nutraceuticals, cosmetics, and veterinary products.
The company’s leadership team brings together expertise in pharmaceutical manufacturing, consumer packaged goods, and botanical extraction. Chief Executive Officer Chris Jones has over 15 years of experience in life sciences and has overseen multiple facilities achieving GMP certification. Chief Scientific Officer Dr. Laura Reynolds holds a Ph.D. in chemical engineering and leads Hempstract’s R&D efforts in formulation science. Chief Financial Officer Michael Pan, previously with a leading global consulting firm, manages the company’s strategic capital initiatives and investor relations. Since its founding in 2017, Hempstract has focused on scalability, product innovation, and regulatory compliance as it seeks to establish a differentiated position in the evolving hemp industry.
AI Generated. May Contain Errors.
Free HPST Stock Alerts